The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 06, 2023
Filed:
Feb. 12, 2020
Applicant:
Allegro Pharmaceuticals, Llc, San Juan Capistrano, CA (US);
Inventors:
Michael John Mackel, Portland, OR (US);
John Park, Santa Ana, CA (US);
Assignee:
Allegro Pharmaceuticals, LLC, San Juan Capistrano, CA (US);
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/08 (2019.01); A61K 38/12 (2006.01); A61K 38/00 (2006.01); A61P 9/10 (2006.01); A61P 27/02 (2006.01); C07K 5/00 (2006.01); C07K 7/00 (2006.01); C07K 16/00 (2006.01); C07K 17/00 (2006.01); A61K 9/08 (2006.01); A61K 38/17 (2006.01); A61K 51/06 (2006.01); A61K 51/08 (2006.01); A61L 27/22 (2006.01); A61L 31/04 (2006.01); A61K 47/64 (2017.01); A61K 38/07 (2006.01); A61K 9/06 (2006.01);
U.S. Cl.
CPC ...
A61K 38/12 (2013.01); A61K 9/08 (2013.01); A61K 38/07 (2013.01); A61K 38/08 (2013.01); A61K 38/1709 (2013.01); A61K 47/64 (2017.08); A61K 51/065 (2013.01); A61K 51/082 (2013.01); A61K 51/088 (2013.01); A61L 27/227 (2013.01); A61L 31/043 (2013.01); C07K 7/00 (2013.01); A61K 9/06 (2013.01); A61L 2300/252 (2013.01);
Abstract
Compounds comprising R-G-Cysteic Acid (i.e., R-G-NH—CH(CH—SOH)COOH or Arg-Gly-NH—CH(CH—SOH)COOH) and derivatives thereof, including pharmaceutically acceptable salts, hydrates, stereoisomers, multimers, cyclic forms, linear forms, drug-conjugates, pro-drugs and their derivatives. Also disclosed are methods for making and using such compounds including methods for inhibiting cellular adhesion to RGD binding sites or delivering other diagnostic or therapeutic agents to RGD binding sites in human or animal subjects.